This session speaks on the emerging trends in the use of digital health daata and the evolution of advanced analytics and technology platforms. Explaining the pressure of the life science industry with mounting pricing pressures, growing demands for evidence, and declining R&D productivity, Jeffrey Morgan emphasizes the importance of unlocking value through the harnessing and democratization of data. Doing so will not only accelerate drug development, but improve evidence generation that supports payer, provider, and patient needs.